An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls

Trial Profile

An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 22 Sep 2017 Planned number of patients changed from 30 to 33.
    • 22 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.
    • 22 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top